- $485.88m
- $260.49m
U.S. STOCKS ON THE MOVE-Vertex Pharma, Duluth, Molecular Templates
U.S. STOCKS ON THE MOVE-BJ's Wholesale, FuelCell Energy, Holley
Neoleukin Therapeutics rises on strategic alternatives plan, job cuts
Brief: Neoleukin Therapeutics Announces Restructuring And Leadership Transition
Neoleukin Therapeutics Inc expected to post a loss of 21 cents a share - Earnings Preview
Neoleukin Therapeutics Inc reports results for the quarter ended in September - Earnings Summary
Brief: Neoleukin Therapeutics Announces Third Quarter 2022 Financial Results
Neoleukin Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
Neoleukin Therapeutics Inc reports results for the quarter ended in June - Earnings Summary
Brief: Neoleukin Therapeutics Reports Qtrly Net Loss Per Share $0.28
Neoleukin rises after Millenium Management discloses 5% passive stake
Brief: Millennium Management Reports 5% Passive Stake In Neoleukin Therapeutics Inc
Brief: Neoleukin Therapeutics Announces First Patient Treated In Combination Arm Of Phase 1 Trial Evaluating NL-201 In Combination With Keytruda
Neoleukin Therapeutics Inc reports results for the quarter ended in March - Earnings Summary
Brief: Neoleukin Therapeutics Files For Offering Of 15.3 Million Shares Of Common Stock By Selling Stockholder - SEC Filing
Neoleukin Therapeutics Inc expected to post a loss of 30 cents a share - Earnings Preview
NASDAQ RESUMED AT 10:06 AM
NASDAQ TRADE HALT VOLATILITY TRADING PAUSE AT 10:02 AM
Brief: Neoleukin Therapeutics Announces Appointment Of Donna Cochener As General Counsel